Warning: Constant WP_CACHE already defined in /home/bicollgroup/public_html/wp-config.php on line 8
Company News - Bicoll GmbH

Bicoll News

Bicoll News 2011

Bicoll Newsletter Edition 2011 Successful joint research project on aurora kinase inhibitors with EMBL (European Molecular Biology Laboratory) Grant from Shanghai Science Technology Committee for Bicoll Biotechnology (Shanghai) Co. Ltd. Enlargement of analytical department and medicinal chemistry team What to …

Read more

BIO-Europe 2010, Munich

Attendee: Dr. Kai Lamottke (Managing Director, Bicoll GmbH)   BIO-Europe is Europe’s largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with …

Read more

6th International Conference Compound libraries

6th International Conference Compound libraries 2010: “Ensuring High Quality Compounds – Successful Library Design and Screening – Outsourcing Strategies – Hit to Lead Optimisation” Attendees: Dr. Kai Lamottke (Managing Director, Bicoll GmbH); Dr. Christian Haug (Managing Director, Bicoll GmbH).

The right match – German SMEs: Challenges, Strategies and Success in a Competitive China

GC Ticker: bi-monthly newsletter of the German Chamber of Commerce, 4, 2010, p. 35

Take a clever business idea, add some profound financing and set up facilities in China is not a
one size fits all guideline for stepping into one of Asia’s biggest economies”, remarked Dr. Kai La-
mottke, General Manager at Bicoll Biotechnology (Shanghai) Co. Ltd. Back in 2000 the company
was founded as a private biopharmaceutical enterprise in Germany offering pre-clinical support
in the area of drug discovery from natural products and medicinal chemistry. Before planning to
setting up its subsidiary in China in 2001, the company’s management was aware that participat-
ing in China’s growth is not a simple proposition. It was clear that building up domestic contacts
first and considering that conducting business in China is different, requiring flexibility and adapt-
ability were necessary components of Bicoll’s strategy, strengthened by the fact that no examples
existed as guidance for the successful establishment of a company like Bicoll. Therefore, a novel
business model tailored for the parallel set-up in Europe and in China was needed to address this.
An early positive cash-flow was one of the most important milestones in Bicoll’s concept.

Read more

Results of research on aurora kinase inhibitors announced

BICOLL GmbH and EMBL have announced the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases.

Aurora kinases have gained a great deal of attention as possible anticancer drug targets because these serine–threonine kinases are frequently overexpressed in human tumours.
For a research project on genetic instability and cellular proliferation caused by aurora kinase expression in several cancer entities, including multiple myeloma, the group of Dr Joe Lewis, Head of Chemical Biology Core Facility at the European Molecular Biology Laboratory (EMBL) Heidelberg, has been searching for novel aurora kinase inhibitors supplementing already known clinical aurora kinase inhibitors such as VX680.
The search for promising compounds was based on the screening of ProfilesTM from BICOLL’s library of plant metabolites.
Dr Lewis explained: ‘Bicoll’s idea of using pooled and fractionated small molecule collections, derived from endemic Asian plants, has already successfully led to the identification of hit compounds in various high-throughput screening processes in other cooperations. We were curious to find out whether natural products could also demonstrate their proof-of-concept for our biochemical screening methods.’
BICOLL provided a set of 1000 Profiles (equal to approximately 3000–10,000 different small molecules) to EMBL’s biochemical screening program, which resulted in 18 hit clusters showing specific kinase activity. Because of the unexpectedly high hit rate of 2 per cent, the group of EMBL researchers elected to focus on four hit clusters for isolation and structure elucidation.
‘Within only three months and a second round of screening, BICOLL identified and structurally elucidated two pure compounds with interesting structural motifs for our client’s further development programs,’ commented Dr Kai Lamottke, Managing Director of BICOLL. ‘Subsequent investigation of our pure natural compound database, using the newly found structural motifs, additionally led to the testing in EMBL’s protein–protein interaction test. Additional compounds for further structure–activity relationship could be identified.’

Read more